

Predictive-adjusted indirect comparison (PAIC): a novel method for population-adjusted indirect comparison

An accurate, unbiased alternative to MAIC

Antonio Remiro Azócar¹, Gianluca Baio¹, Anna Heath^{1,2,3}

¹Department of Statistical Science, University College London; ²The Hospital for Sick Children; ³University of Toronto
ISPOR Europe 2019, Bella Center, Copenhagen, 4 November 2019

Background

Population-adjusted indirect comparisons are increasingly used to compare treatment outcomes across clinical trials. Such methods are utilised when:

- There are no head-to-head trials comparing the interventions of interest
- Individual patient data (IPD) are available for an intervention, e.g. through the sponsor company's own trial, but are unavailable for comparator(s)
- There are cross-trial differences in patients' baseline characteristics

Suppose that we want to compare treatment *A* with treatment *B* in the absence of a head-to-head randomised controlled trial. An **indirect** comparison is required. We shall assume that this is **anchored**: a connected treatment network is available through a common comparator *C*, e.g. placebo. We have IPD for the index trial *AC* but only aggregate-level data (ALD), available from publications, for trial *BC*.

Standard methods for indirect comparisons allow for the use of ALD and maintain randomisation. However, such methods are biased when the distribution of effect modifiers differs between trials. Population-adjusted indirect comparisons adjust for cross-trial differences in observed covariates. Recently proposed approaches for population adjustment are:

1. **Matching-adjusted indirect comparison (MAIC)** [1] reweights the patients in the *AC* trial so that the weighted moments of their covariates match those in the published *BC* summary data. Weights derived from the IPD are applied to the outcome model to generate adjusted outcomes. As MAIC is a weighting method, it will always reduce the effective sample size. If too many covariates are included in the weighting procedure, the precision of the treatment effect estimate may be negatively affected [2].
2. **Simulated treatment comparison (STC)** [3] involves creating an outcome regression model. A regression model is fitted in the *AC* population, including all effect modifiers in imbalance, and then used to predict outcomes in the *BC* trial population. The current implementation of STC is systematically biased for non-linear outcomes because the mean outcome depends on the full distribution of the covariates and not just their mean [2, 4].

To overcome possible shortcomings of current population adjustment methods, we propose a multiple imputation-based algorithm called **predictive-adjusted indirect comparison (PAIC)**.

Methodology

Available data

For the *AC* (IPD) trial, we have:

- A vector of *K* observed baseline characteristics for each patient *i*, $\mathbf{X}_i = (X_{i1}, \dots, X_{iK})$
- A treatment indicator T_i ($T_i = 1$ for active treatment and $T_i = 0$ for the common comparator)
- An observed outcome Y_i , e.g. a binary or time-to-event outcome

For the *BC* (ALD) trial, we have:

- The published summary values θ of the covariates, e.g. proportions for discrete X_{ik}
- An estimate of the *B* vs. *C* treatment effect (in the *BC* population), $\hat{\Delta}_{CB}$

Predictive-adjusted indirect comparison

Predictive-adjusted indirect comparison consists of six steps: **first-stage regression**, **covariate sampling**, **outcome prediction**, **second-stage regression**, **pooling** and **comparison**. The algorithm methodology is summarised in **Figure 1**. A regression fitted in the *AC* (IPD) population (step 1) is used to create a large number of “synthetic” datasets/imputations (steps 2 and 3); these consist of predicted individual-level covariates and outcomes under treatments *A* and *C* in the *BC* population, $(T_i, \mathbf{X}_i^*, Y_i^*)$. The *A* vs. *C* treatment effect on such population is estimated in a second-stage regression for each imputation (step 4). After pooling over imputations (step 5), the average *A* vs. *C* treatment effect can be compared with $\hat{\Delta}_{CB}$ (step 6) to obtain an unbiased estimate of comparative efficacy for *A* vs. *B*.

Simulation Study

A simulation study is performed to benchmark the performance of PAIC against that of MAIC and STC. Binary outcomes and four binary covariates (two effect modifiers and two purely prognostic variables) are considered. 1000 Monte Carlo replicates are generated and analysed per simulation scenario. The study follows a fully factorial structure with $3 \times 3 \times 3 \times 2 \times 3 = 162$ scenarios. The following parameters are varied:

- $N_{AC} \in \{300, 450, 600\}$ under a 2:1 active treatment vs. placebo allocation ratio
- $\beta_{1k} \in \{-\log(0.67), -\log(0.5), -\log(0.33)\}$ (weak, moderate and strong prognostic effect)
- $\beta_{2k} \in \{-\log(0.67), -\log(0.5), -\log(0.33)\}$ (weak, moderate and strong effect modification)
- $\text{cor}(X_{ij}, X_{ik}) \in \{0, 0.35\}$, $j \neq k$ (zero and strong covariate correlation)
- $p_k \in \{0.4, 0.35, 0.3\}$, $X_{ik} \sim \text{Bernoulli}(p_k)$ for the *AC* trial (simultaneously varying $p_k \in \{0.6, 0.65, 0.7\}$ for the *BC* trial, respectively, yielding weak, moderate and strong covariate imbalance)

Binary outcomes Y_i are simulated from Bernoulli distributions with probabilities of success generated from logistic regression. For each trial:

$$\text{logit}(P(Y_i|T_i, \mathbf{X}_i)) = \beta_0 + \mathbf{X}_i\beta_1 + (\beta_T + \mathbf{X}_i^{EM}\beta_2)\mathbf{1}(T_i = 1),$$

with $\beta_T = \log(0.17)$, β_0 set to fix the baseline event rate at 0.35 and $N_{BC} = 600$ (2:1 allocation). For PAIC, the number of imputations is set to $M = 100$.

Conclusions

- PAIC produces more accurate estimates (lower mean absolute error) than MAIC and STC on a consistent basis
- PAIC withstands extreme conditions better than MAIC and STC; MAIC is less robust to strong covariate imbalances and STC breaks down with strong prognostic variable effects and is more sensitive to low numbers of patients in the IPD trial
- PAIC provides unbiased estimates when all effect modifiers are accounted for
- In general, PAIC's coverage rates were not statistically significantly different from 0.95




Figure 1: Predictive-adjusted indirect comparison




Figure 2: Mean absolute error




Figure 3. Coverage rate of 95% confidence intervals

References

- [1] J. E. Signorovitch et al. (2010). *Pharmacoeconomics* 28(10), 935-945.
- [2] D. Phillippo et al. (2016). *NICE DSU technical support document 18*.
- [3] J. J. Caro & K. J. Ishak (2010). *Pharmacoeconomics* 28(10), 957-967.
- [4] K.J. Ishak et al. (2015). *Value in Health* 18(7), p.A719.